These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16838823)

  • 21. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
    Masi G; Pfanner C; Millepiedi S; Berloffa S
    J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
    Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
    Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
    Wheaton MG; Rosenfield D; Foa EB; Simpson HB
    J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
    J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.
    Romanelli RJ; Wu FM; Gamba R; Mojtabai R; Segal JB
    Depress Anxiety; 2014 Aug; 31(8):641-52. PubMed ID: 24390912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Issues in the pharmacological treatment of obsessive-compulsive disorder.
    Math SB; Janardhan Reddy YC
    Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy for obsessive-compulsive disorder.
    Hollander E; Kaplan A; Allen A; Cartwright C
    Psychiatr Clin North Am; 2000 Sep; 23(3):643-56. PubMed ID: 10986733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
    Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
    J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic treatment in obsessive-compulsive disorder: a literature review.
    Keuneman RJ; Pokos V; Weerasundera R; Castle DJ
    Aust N Z J Psychiatry; 2005 May; 39(5):336-43. PubMed ID: 15860020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy in children and adolescents with obsessive-compulsive disorder.
    Grados M; Scahill L; Riddle MA
    Child Adolesc Psychiatr Clin N Am; 1999 Jul; 8(3):617-34, x. PubMed ID: 10442233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.
    Sareen J; Kirshner A; Lander M; Kjernisted KD; Eleff MK; Reiss JP
    J Affect Disord; 2004 Oct; 82(2):167-74. PubMed ID: 15488245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study.
    Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M
    J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypochondriasis and its relationship to obsessive-compulsive disorder.
    Fallon BA; Qureshi AI; Laje G; Klein B
    Psychiatr Clin North Am; 2000 Sep; 23(3):605-16. PubMed ID: 10986730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.